NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

On iVil, erniewerner posted the following naysayer argument.

"If there was any likelihood of a positive outcome [for PFS], why would the company avoid doing the primary analysis? Why the lengthy delay that entails the death spiral financing?"

This argument does seem to make sense, in particular due to the harshness of the drop due to the large dilution and toxic financing made necessary due to the wait while withholding the "positive" PFS endpoint results of the PIII while remaining blinded to the OS data so that it could continue to accumulate as long as deemed necessary by management.

What are the counter arguments to this, denizens of iHub?